Market Risers: Kingfisher, Lloyds Banking Group, N4 Pharma

Broker Ratings

The share price for Kingfisher ticker code: LON:KGF has moved up 2.58% or 7.2 points throughout today’s trading session so far. Investors have remained positive throughout the session. Range high for the period so far is 292.2 and hitting a low of 284.63. The total volume traded so far comes to 2,168,472 while the average shares exchanged is 8,298,505. The 52 week high for the shares is 326.2 equating to 46.7 points in difference to the previous days close of business and a 52 week low sitting at 101 a difference of some 178.5 points. Kingfisher now has a 20 SMA at 279.03 with a 50 day moving average of 284.29. The market capitalisation currently stands at £6,048.86m at the time of this report. The share price is in Great British pence. Mcap is measured in GBP. This article was written with the last trade for Kingfisher being recorded at Tuesday, January 12, 2021 at 11:52:54 AM GMT with the stock price trading at 286.7 GBX.

Stock in Lloyds Banking Group found using EPIC: LON:LLOY has climbed 2.13% or 0.77 points in today’s trading session so far. Market buyers have remained optimistic during this period. The high for the period has reached 37.08 dropping as low as 36.33. The number of shares traded by this point in time totalled 56,987,159 with the daily average number around 262,574,450. The 52 week high price for the shares is 60.06 which comes in at 23.89 points difference from the previous days close and putting the 52 week low at 23.59 which is a variance of 12.58 points. Lloyds Banking Group now has a 20 simple moving average of 37.24 with a 50 day MA at 36.35. The market capitalisation is now £26,160.84m at the time of this report. The currency for this stock is Great British pence.Market cap is measured in GBP. This article was written with the last trade for Lloyds Banking Group being recorded at Tuesday, January 12, 2021 at 11:52:58 AM GMT with the stock price trading at 36.94 GBX.

The share price for N4 Pharma company symbol: LON:N4P has increased 4.76% or 0.4 points throughout the session so far. Traders have remained positive throughout the trading session. Range high for the period has seen 9 while the low for the session was 8.1. The total volume of shares exchanged through this period comes to 1,696,042 with the daily average at 6,588,232. The 52 week high for the shares is 16 about 7.6 points difference from the previous days close and putting the 52 week low at 2 a difference of some 6.4 points. N4 Pharma now has a 20 SMA at 8.63 and the 50 day moving average of 8.18. Market capitalisation is now £15.94m at the time of this report. The share price is in GBX. Mcap is measured in GBP. This article was written with the last trade for N4 Pharma being recorded at Tuesday, January 12, 2021 at 11:44:27 AM GMT with the stock price trading at 8.8 GBX.

Share on:

Latest Company News

Lloyds Banking Group to acquire Curve in digital expansion move

Lloyds Banking Group has agreed to acquire Curve, the London fintech known for its digital wallet platform that brings multiple cards and payment options into one app.

Lloyds Banking Group flags potential additional provision on Motor Finance

Lloyds Banking Group has confirmed it is assessing the FCA’s consultation paper on motor finance and expects an additional provision may be required, which could be material.

Kingfisher Plc reports strong H1 2025/26, upgraded profit and cash flow guidance

Kingfisher PLC delivered a solid first half to 31 July 2025, reporting adjusted pre-tax profit up 10.2% to £368m and free cash flow rising 13.5% to £478m. Like-for-like sales grew 1.9%, supported by strong performances from B&Q and Screwfix, alongside double-digit growth in trade and e-commerce.

Kingfisher Plc completes £50m first tranche of £300m share buyback

Kingfisher plc completes the first tranche of its £300m share repurchase program, buying 17.9 million shares for £50m through Goldman Sachs.

Kingfisher Plc reports Q1 sales growth and reiterates FY guidance

Kingfisher PLC (LON:KGF) has released its impressive Q1 trading update for 2025, highlighting robust sales growth and a positive outlook for the year ahead.

    Search

    Search